| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return |
|---|---|---|---|---|---|
|
NVCT
Nuvectis Pharma
|
Jun 22, 2026 | BUY |
Strong Buy
+10.6% avg upside
6 analysts
|
$22.00
7.76% Downside
|
· |
|
CRDF
Cardiff Oncology
|
Jun 05, 2026 | BUY |
Strong Buy
+686.4% avg upside
18 analysts
|
$4.00
208.87% Upside
|
-19.3% |
|
NXTC
NextCure
|
Jun 02, 2026 | BUY |
Strong Buy
+887.1% avg upside
10 analysts
|
$25.00
1276.97% Upside
|
· |
|
FTH
Faeth Therapeutics
|
May 28, 2026 | BUY |
Strong Buy
+61.8% avg upside
12 analysts
|
$50.00
89.42% Upside
|
· |
|
ACTU
Actuate Therapeutics, Inc.
|
May 18, 2026 | BUY |
Strong Buy
+569.6% avg upside
4 analysts
|
$5.00
153.76% Upside
|
-16.9% |
|
RLMD
Relmada Therapeutics
|
Mar 02, 2026 | BUY |
Buy
+109.9% avg upside
15 analysts
|
$14.00
114.10% Upside
|
+34.5% |
|
TVRD
Tvardi Therapeutics
|
Feb 04, 2026 | BUY |
Buy
+651.0% avg upside
23 analysts
|
$6.00
146.86% Upside
|
-14.5% |
|
ANL
Adlai Nortye Ltd. Sponsored ADR
|
Jan 29, 2026 | BUY |
Strong Buy
+98.7% avg upside
6 analysts
|
$11.00
1.86% Upside
|
+106.9% |
|
AAPG
Ascentage Pharma Group International Unsponsored ADR
|
Dec 15, 2025 | BUY |
Strong Buy
+157.2% avg upside
10 analysts
|
$50.00
192.94% Upside
|
-37.6% |
|
IPHA
Innate Pharma
|
Oct 23, 2025 | BUY |
Strong Buy
+246.3% avg upside
10 analysts
|
$8.00
321.25% Upside
|
-7.8% |
|
LYEL
Lyell Immunopharma
|
Sep 26, 2025 | BUY |
Buy
+93.9% avg upside
10 analysts
|
$20.00
56.72% Upside
|
-6.7% |
|
ADAG
Adagene
|
Sep 18, 2025 | BUY |
Strong Buy
+81.0% avg upside
8 analysts
|
$9.00
116.41% Upside
|
+59.9% |
|
GNLX
Genelux Corp.
|
Jul 21, 2025 | BUY |
Strong Buy
+528.6% avg upside
7 analysts
|
$10.00
243.65% Upside
|
-13.4% |
|
NBP
NovaBridge Biosciences
|
May 28, 2025 | BUY |
Strong Buy
+1222.3% avg upside
14 analysts
|
$5.00
213.53% Upside
|
· |
|
EXEL
Exelixis
|
May 14, 2025 | HOLD |
Strong Buy
-22.2% avg upside
33 analysts
|
$37.00
29.96% Downside
|
+14.4% |
|
NRIX
Nurix Therapeutics
|
Apr 09, 2025 | BUY |
Strong Buy
+60.1% avg upside
26 analysts
|
$36.00
86.15% Upside
|
+69.2% |
|
CATX
Perspective Therapeutics
|
Jan 27, 2025 | BUY |
Strong Buy
+275.0% avg upside
22 analysts
|
$20.00
579.11% Upside
|
-29.5% |
|
IDYA
IDEAYA Biosciences
|
Feb 21, 2024 | BUY |
Strong Buy
+34.1% avg upside
29 analysts
|
$50.00
36.51% Upside
|
-50.7% |
|
COGT
Cogent Biosciences
|
Feb 20, 2024 | BUY |
Strong Buy
-0.9% avg upside
26 analysts
|
— | -5.8% |
|
RLAY
Relay Therapeutics
|
Feb 13, 2024 | BUY |
Strong Buy
+10.8% avg upside
19 analysts
|
$18.00
0.40% Downside
|
-56.0% |
|
NUVL
Nuvalent
|
Jan 08, 2024 | HOLD |
Buy
-0.3% avg upside
21 analysts
|
$69.00
44.07% Downside
|
+7.5% |
|
CCCC
C4 Therapeutics
|
Dec 13, 2023 | BUY |
Strong Buy
+323.1% avg upside
19 analysts
|
$14.00
233.43% Upside
|
-20.5% |
|
ARVN
Arvinas Holding Company
|
Dec 08, 2023 | BUY |
Strong Buy
+247.4% avg upside
27 analysts
|
$77.00
849.40% Upside
|
-24.1% |
|
GLUE
Monte Rosa Therapeutics
|
Nov 09, 2023 | HOLD |
Strong Buy
+12.7% avg upside
14 analysts
|
$5.00
76.23% Downside
|
+180.6% |
|
ZVRA
Zevra Therapeutics
|
Aug 09, 2018 | BUY |
Strong Buy
+83.1% avg upside
15 analysts
|
$13.00
0.26% Downside
|
-72.2% |
|
VNDA
Vanda
|
Aug 02, 2018 | BUY |
Strong Buy
+246.6% avg upside
13 analysts
|
$27.00
356.80% Upside
|
-29.4% |
|
TEVA
Teva Pharmaceutical
|
Aug 02, 2018 | HOLD |
Buy
-12.7% avg upside
39 analysts
|
— | -63.6% |
|
HRTX
Heron Therapeutics
|
Jul 27, 2018 | HOLD |
Strong Buy
+6215.7% avg upside
21 analysts
|
— | -50.5% |
|
PCRX
Pacira Pharmaceuticals
|
Jul 27, 2018 | HOLD |
Buy
+63.2% avg upside
21 analysts
|
— | +7.2% |
|
TPST
Tempest Therapeutics
|
Jul 06, 2018 | HOLD |
Buy
+1744.8% avg upside
18 analysts
|
— | -12.0% |
|
TRVN
Trevena
|
Jul 06, 2018 | HOLD |
Buy
+358909.0% avg upside
11 analysts
|
— | · |
|
PRGO
Perrigo Company
|
Jul 06, 2018 | HOLD |
Buy
+599.5% avg upside
20 analysts
|
— | -33.2% |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.